Altre lingue Devyser Diagnostics AB

Azioni

DVYSR

SE0016588867

Biotecnologia

Tempo differito Nasdaq Stockholm Altri mercati azionari 12:31:34 10/02/2026			Variaz. 5gg	Var. 1 gen.
107,00 ^SEK	-1,83%		+1,32%	-6,13%

28/01	Devyser Diagnostics della Svezia firma un accordo di fornitura con Illumina	MT
28/01	Devyser sigla un accordo strategico di fornitura con Illumina	RE

Altre lingue

03/02	Invitation to presentation of Devyser’s Q4 2025 Interim Report
28/01	Sweden's Devyser Diagnostics Signs Supply Deal With Illumina
28/01	The Dollar's Drop Is a Warning Shot
28/01	Devyser enters strategic supply agreement with Illumina
28/01	Devyser Enters Strategic Supply Agreement with Illumina to Offer Sequencing Instruments and Products
15/12	Devyser Diagnostics Wins Cystic Fibrosis Tests Tender in Norway
15/12	Devyser wins Norwegian tender for Devyser CFTR at Oslo University Hospital
15/12	Devyser Wins Norwegian Tender for Devyser CFTR At Oslo University Hospital
08/12	Devyser Bags SEK9.5 Million Tender for Genetic Testing Kit in France
08/12	Devyser wins four-year tender in France
08/12	Devyser Secures Four-Year Tender in France for Devyser Compact
04/12	Devyser Diagnostics Wins In Vitro Diagnostic Device Classification for Post-transplant Monitoring Products
04/12	Devyser Diagnostics AB Announces Health Canada Grants IVD Approval to Devyser's NGS -Based Chimerism Test
28/11	Cms sets price for Devyser's Prenataldetect RhD test at $192
28/11	Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
25/11	Devyser Diagnostics Enrolls First Patient in Kidney Transplant Study
25/11	Devyser Advances U.S. Clinical Strategy with First Patient Enrolled in Devyser Accept Cfdna Study
07/11	Devyser Diagnostics (Q3 Review) - Exaggerated reaction, strong Q4 ahead
05/11	Devyser Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
05/11	Devyser Diagnostics AB publishes quarterly report for the period July to September 2025
04/11	Devyser Announces Next-Generation Sequencing (NGS ) Based CFTR Assay Is Now Compliance Under the European in Vitro Diagnostic Regulation
29/10/25	Invitation to presentation of Devyser’s Q3 2025 Interim Report
22/09/25	Bulletin from an Extraordinary General Meeting in Devyser Diagnostics AB (publ) held on 22 September 2025
03/09/25	Devyser Diagnostics CEO buys SEK 508,682 worth of co's shares
22/07/25	Devyser Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue Devyser Diagnostics AB

Azioni

DVYSR

SE0016588867

Biotecnologia

Altre lingue

Filtri